ClinicalTrials.gg
CompletedNCT00293033Updated Nov 18, 2019Results posted

Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects

A Phase 3 interventional study of BEMA™ and Placebo in Pain and Cancer, sponsored by BioDelivery Sciences International. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.

Sponsored by BioDelivery Sciences International · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,882 studies in Pain with a site in United States — 313 open to participants now, 392 under way, 24 of them phase 3. Pain · United States.

Enrollment
627th of 2,560
152 · median 66
Started
2006
with 106 others
Phase 3
343 of 2,882
17 open now
Registered
199th of 2,882
by date

Among the 2,882 studies in Pain with a site in United States, this one is the 627th largest by enrollment of the 2,560 interventional ones that give a count, is one of 107 that started in 2006, is one of 343 in phase 3, and was the 199th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

313 of the 2,882 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

308 more — sign in →

All 313 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,882 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of BEMA Fentanyl (Onsolis) at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy. The standard of care for these breakthrough pain episodes is a rapid onset, short acting analgesic with minimal associated sleepiness. Oral morphine, oxycodone and hydromorphone are routinely used, but because of slow and variable oral absorption, the pain control is not the best with these products. Oral transmucosal fentanyl citrate (OTFC) has been used successfully in treating breakthrough pain episodes associated with cancer. OTFC is a lozenge of fentanyl on a stick and is administered by continuously swabbing the interior of the subject's mouth until the product is dissolved (approximately 15 to 30 minutes). The buccal route of administration avoids the delay and variability associated with oral absorption.

Read the detailed description

This is a randomized, double-blind, placebo controlled, multiple cross-over study. Eligible subjects will be treated with open label BEMA fentanyl over a period of up to two weeks. Doses will be titrated upward, starting at 200 μg, until a dose is identified that produces satisfactory pain relief for at least 2 episodes. Those subjects who identify a dose of BEMA fentanyl that produces satisfactory relief of breakthrough pain episodes will enter the double-blind, placebo controlled period of the trial. They will receive 3 placebo doses and 6 BEMA fentanyl doses in a random sequence per randomization schedule.

03

Conditions studied

  • Pain
  • Cancer

Keywords

  • Breakthrough Pain in Patients with Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant and non-lactating female. A female of is eligible to participate in this study if she is using an acceptable method of .
  • 18 years or older
  • Patient must have pain associated with cancer or cancer treatment.
  • Patient must be on a stable current regimen of oral opioids equivalent to 60 - 1000 mg/day of oral morphine or 50 - 300 µg/hr of transdermal fentanyl (e.g. oxycodone 30 mg, methadone 20 mg, and hydromorphone 7.5 mg).
  • Regularly experiences 1 - 4 breakthrough pain episodes per day that require additional opioids for pain control
  • At least partial relief of breakthrough pain by use of opioid therapy
  • Subject must be able to self-administer the study medication correctly.
  • Subject must be willing and able to complete the electronic diary card with each pain episode.
  • Signed consent must be obtained at screening prior to any procedures being performed.

Exclusion criteria

Exclusion Criteria:

  • Psychiatric/cognitive or neurological impairment that would limit the subject's ability to understand or complete the diary
  • Cardiopulmonary disease that, in the opinion of the investigator, would significantly increase the risk of respiratory depression
  • Recent history or current evidence of alcohol or other drug substance (licit or illicit) abuse
  • Rapidly escalating pain that the investigator believes may require an increase in the dosage of background pain medication during the study
  • Moderate (Grade 3) to severe (Grade 4) mucositis (Subjects with less than moderate mucositis are permitted and must be instructed to not apply the BEMA disc at a site of inflammation.)
  • Strontium 89 therapy within the previous 6 months
  • Any other therapy prior to the study that the investigator considers could alter pain or the response to pain medication.
  • Use of an drug within 4 weeks preceding this study
  • History of or intolerance to fentanyl
  • Regularly more than 4 episodes per day
  • (ECOG) performance status of 4 or 5
  • Subject is pregnant, actively trying to become pregnant, breast feeding or not using adequate measures
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
152 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: BEMA™ · Drug: Placebo

  • Experimental
    BEMA™ Fentanyl

    BioErodible MucoAdhesive (BEMA) Fentanyl

    Drug: BEMA™

Interventions

  • DrugBEMA™

    BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.

    Also known as: Onsolis (fentanyl buccal soluble film)

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Summary of Pain Intensity Differences (SPID)

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.

    Time frame: 0-30 minutes

Secondary outcomes

  1. SPID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.

    Time frame: 0-5 minutes

  2. SPID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.

    Time frame: 0-10 minutes

  3. SPID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.

    Time frame: 0-15 minutes

  4. SPID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.

    Time frame: 0-45 minutes

  5. SPID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.

    Time frame: 0-60 minutes

  6. PID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

    Time frame: 5 minutes after dosing

  7. PID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

    Time frame: 10 minutes after dosing

  8. PID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

    Time frame: 15 minutes after dosing

  9. PID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

    Time frame: 30 minutes after dosing

  10. PID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

    Time frame: 45 minutes after dosing

  11. PID

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

    Time frame: 60 minutes after dosing

  12. Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

    Time frame: 5 minutes after dosing

  13. Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

    Time frame: 10 minutes after dosing

  14. Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

    Time frame: 15 minutes after dosing

  15. Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

    Time frame: 30 minutes after dosing

  16. Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

    Time frame: 45 minutes after dosing

  17. Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

    Time frame: 60 minutes after dosing

  18. Total Pain Relief

    Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

    Time frame: 5 minutes

  19. Total Pain Relief

    Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

    Time frame: 10 minutes

  20. Total Pain Relief

    Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

    Time frame: 15 minutes

  21. Total Pain Relief

    Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

    Time frame: 30 minutes

  22. Total Pain Relief

    Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

    Time frame: 45 minutes

  23. Total Pain Relief

    Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

    Time frame: 60 minutes

  24. Subject Overall Satisfaction With Study Drug

    Subjects evaluated their overall satisfaction with study drug at the time rescue medication was consumed or at the 60-minute time point using a 5-point categorical scale (0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent).

    Time frame: 60 minutes or at time of rescue medication use

  25. Percentage of Pain Free Episodes

    A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

    Time frame: 5 minutes

  26. Percentage of Pain Free Episodes

    A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

    Time frame: 10 minutes

  27. Percentage of Pain Free Episodes

    A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

    Time frame: 15 minutes

  28. Percentage of Pain Free Episodes

    A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

    Time frame: 30 minutes

  29. Percentage of Pain Free Episodes

    A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

    Time frame: 45 minutes

  30. Percentage of Pain Free Episodes

    A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

    Time frame: 60 minutes

  31. Episodes With at Least 50% Decreases in Pain

    Number of episodes where the total pain score has at least a 50% reduction from baseline.

    Time frame: 15 minutes

  32. Episodes With at Least 50% Decreases in Pain

    Number of episodes where the total pain score has at least a 50% reduction from baseline.

    Time frame: 30 minutes

  33. Episodes With at Least 50% Decreases in Pain

    Number of episodes where the total pain score has at least a 50% reduction from baseline.

    Time frame: 45 minutes

  34. Episodes With at Least 50% Decreases in Pain

    Number of episodes where the total pain score has at least a 50% reduction from baseline.

    Time frame: 60 minutes

  35. Episodes With at Least 33% Decreases in Pain

    Number of episodes where the total pain score has at least a 33% reduction from baseline.

    Time frame: 15 minutes

  36. Episodes With at Least 33% Decreases in Pain

    Number of episodes where the total pain score has at least a 33% reduction from baseline.

    Time frame: 30 minutes

  37. Episodes With at Least 33% Decreases in Pain

    Number of episodes where the total pain score has at least a 33% reduction from baseline.

    Time frame: 45 minutes

  38. Episodes With at Least 33% Decreases in Pain

    Number of episodes where the total pain score has at least a 50% reduction from baseline.

    Time frame: 60 minutes

  39. Episodes With Complete Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

    Time frame: 5 minutes

  40. Episodes With Complete Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

    Time frame: 10 minutes

  41. Episodes With Complete Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

    Time frame: 15 minutes

  42. Episodes With Complete Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

    Time frame: 30 minutes

  43. Episodes With Complete Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

    Time frame: 45 minutes

  44. Episodes With Complete Pain Relief

    Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

    Time frame: 60 minutes

  45. Rescue Medication Usage

    Rescue medication is medication taken if adequate pain relief is not realized within 30 minutes following application of the study drug. Percentage of episodes when rescue medication was used per subject is analyzed.

    Time frame: 28 Days

Other outcomes

  1. SPID in Neuropathic Pain Subpopulation

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.

    Time frame: 15 minutes

  2. SPID in Neuropathic Pain Subpopulation

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.

    Time frame: 30 minutes

  3. SPID in Neuropathic Pain Subpopulation

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.

    Time frame: 45 minutes

  4. SPID in Neuropathic Pain Subpopulation

    Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.

    Time frame: 60 minutes

07

Results

Posted Oct 21, 2019
Limitations and caveats
There were no limitations or caveats.

Participant flow

24FEB2006 to 14MAR2007

Open-label Titration Period
Participant flow — Open-label Titration Period
MilestoneOnsolis
Started151
Completed82
Not completed69
Withdrew: Adverse event10
Withdrew: Death3
Withdrew: Lack of efficacy5
Withdrew: Protocol violation2
Withdrew: Withdrawal by subject22
Withdrew: Noncompliance and other27
Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestoneOnsolis
Started82
Completed70
Not completed12
Withdrew: Adverse event3
Withdrew: Lack of efficacy1
Withdrew: Withdrawal by subject4
Withdrew: Noncompliance4

Outcome measures

PrimarySummary of Pain Intensity Differences (SPID)

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.

Time frame:
0-30 minutes
Reported as:
Least squares mean · Score on a scale
Summary of Pain Intensity Differences (SPID)
Score on a scaleOnsolisPlacebo
Summary of Pain Intensity Differences (SPID)47.9 ± 3.8738.1 ± 4.3
Statistical analysis
  • Onsolis vs Placebo · Mixed Models Analysis · p = 0.004 · Mean difference (final values): 9.74 · 95% CI 3.31 to 16.18Onsolis minus placebo
SecondarySPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.

Time frame:
0-5 minutes
Reported as:
Least squares mean · Scores on a scale
SPID
Scores on a scaleOnsolisPlacebo
SPID1.8 ± 0.301.5 ± 0.36
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.440 · Mean difference (final values): 0.25 · 95% CI -0.40 to 0.91
SecondarySPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.

Time frame:
0-10 minutes
Reported as:
Least squares mean · Scores on a scale
SPID
Scores on a scaleOnsolisPlacebo
SPID5.9 ± 0.804.9 ± 0.90
Statistical analysis
  • Onsolis vs Placebo · Mixed Models Analysis · p = 0.179 · Mean difference (final values): 0.94 · 95% CI -0.44 to 2.33
SecondarySPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.

Time frame:
0-15 minutes
Reported as:
Least squares mean · Scores on a scale
SPID
Scores on a scaleOnsolisPlacebo
SPID12.8 ± 1.4710.4 ± 1.61
Statistical analysis
  • Onsolis vs Placebo · Mixed Models Analysis · p = 0.047 · Mean difference (final values): 2.32 · 95% CI 0.04 to 4.61
SecondarySPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.

Time frame:
0-45 minutes
Reported as:
Least squares mean · Scores on a scale
SPID
Scores on a scaleOnsolisPlacebo
SPID90.5 ± 6.6370.8 ± 7.41
Statistical analysis
  • Onsolis vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 19.68 · 95% CI 8.50 to 30.86
SecondarySPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome.SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest.

Time frame:
0-60 minutes
Reported as:
Least squares mean · Scores on a scale
SPID
Scores on a scaleOnsolisPlacebo
SPID138.0 ± 9.41106.0 ± 10.58
Statistical analysis
  • Onsolis vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 31.98 · 95% CI 15.85 to 48.12
SecondaryPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

Time frame:
5 minutes after dosing
Reported as:
Mean · Scores on a scale
PID
Scores on a scaleOnsolisPlacebo
PID0.3 ± 0.040.3 ± 0.06
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.517
SecondaryPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

Time frame:
10 minutes after dosing
Reported as:
Mean · Scores on a scale
PID
Scores on a scaleOnsolisPlacebo
PID0.8 ± 0.070.7 ± 0.08
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.458
SecondaryPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

Time frame:
15 minutes after dosing
Reported as:
Mean · Scores on a scale
PID
Scores on a scaleOnsolisPlacebo
PID1.4 ± 0.091.2 ± 0.10
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.223
SecondaryPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

Time frame:
30 minutes after dosing
Reported as:
Mean · Scores on a scale
PID
Scores on a scaleOnsolisPlacebo
PID2.5 ± 0.111.9 ± 0.14
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.015
SecondaryPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

Time frame:
45 minutes after dosing
Reported as:
Mean · Scores on a scale
PID
Scores on a scaleOnsolisPlacebo
PID3.0 ± 0.132.3 ± 0.17
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.001
SecondaryPID

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point.

Time frame:
60 minutes after dosing
Reported as:
Mean · Scores on a scale
PID
Scores on a scaleOnsolisPlacebo
PID3.3 ± 0.132.4 ± 0.18
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryPain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

Time frame:
5 minutes after dosing
Reported as:
Mean · Scores on a scale
Pain Relief
Scores on a scaleOnsolisPlacebo
Pain Relief0.4 ± 0.040.4 ± 0.06
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.193
SecondaryPain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

Time frame:
10 minutes after dosing
Reported as:
Mean · Scores on a scale
Pain Relief
Scores on a scaleOnsolisPlacebo
Pain Relief0.8 ± 0.050.7 ± 0.06
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.113
SecondaryPain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

Time frame:
15 minutes after dosing
Reported as:
Mean · Scores on a scale
Pain Relief
Scores on a scaleOnsolisPlacebo
Pain Relief1.1 ± 0.051.0 ± 0.07
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.192
SecondaryPain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

Time frame:
30 minutes after dosing
Reported as:
Mean · Scores on a scale
Pain Relief
Scores on a scaleOnsolisPlacebo
Pain Relief1.7 ± 0.051.3 ± 0.08
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.002
SecondaryPain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

Time frame:
45 minutes after dosing
Reported as:
Mean · Scores on a scale
Pain Relief
Scores on a scaleOnsolisPlacebo
Pain Relief1.9 ± 0.061.5 ± 0.09
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.002
SecondaryPain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief) at 5, 10, 15, 30, 45, and 60 minutes after taking the study medication or until rescue.

Time frame:
60 minutes after dosing
Reported as:
Mean · Scores on a scale
Pain Relief
Scores on a scaleOnsolisPlacebo
Pain Relief2.1 ± 0.061.6 ± 0.09
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryTotal Pain Relief

Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest.Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

Time frame:
5 minutes
Reported as:
Mean · Scores on a scale
Total Pain Relief
Scores on a scaleOnsolisPlacebo
Total Pain Relief2.2 ± 0.211.8 ± 0.28
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.157
SecondaryTotal Pain Relief

Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

Time frame:
10 minutes
Reported as:
Mean · Scores on a scale
Total Pain Relief
Scores on a scaleOnsolisPlacebo
Total Pain Relief6.1 ± 0.405.2 ± 0.54
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.278
SecondaryTotal Pain Relief

Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

Time frame:
15 minutes
Reported as:
Mean · Scores on a scale
Total Pain Relief
Scores on a scaleOnsolisPlacebo
Total Pain Relief11.6 ± 0.629.8 ± 0.82
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.062
SecondaryTotal Pain Relief

Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

Time frame:
30 minutes
Reported as:
Mean · Scores on a scale
Total Pain Relief
Scores on a scaleOnsolisPlacebo
Total Pain Relief36.1 ± 1.3029.5 ± 1.79
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.002
SecondaryTotal Pain Relief

Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

Time frame:
45 minutes
Reported as:
Mean · Scores on a scale
Total Pain Relief
Scores on a scaleOnsolisPlacebo
Total Pain Relief64.2 ± 2.0552.3 ± 2.93
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.005
SecondaryTotal Pain Relief

Total Pain Relief (TOTPAR) is calculated as the weighted sum of the pain relief (PR) of all time points at or prior to the time point of interest. Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief)compared to baseline (pre-dose)

Time frame:
60 minutes
Reported as:
Mean · Scores on a scale
Total Pain Relief
Scores on a scaleOnsolisPlacebo
Total Pain Relief94.8 ± 2.8476.0 ± 4.16
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.001
SecondarySubject Overall Satisfaction With Study Drug

Subjects evaluated their overall satisfaction with study drug at the time rescue medication was consumed or at the 60-minute time point using a 5-point categorical scale (0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent).

Time frame:
60 minutes or at time of rescue medication use
Reported as:
Mean · Scores on a scale
Subject Overall Satisfaction With Study Drug
Scores on a scaleOnsolisPlacebo
Subject Overall Satisfaction With Study Drug2.0 ± 0.061.5 ± 0.10
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryPercentage of Pain Free Episodes

A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

Time frame:
5 minutes
Reported as:
Mean · percentage of episodes
Percentage of Pain Free Episodes
percentage of episodesOnsolisPlacebo
Percentage of Pain Free Episodes1.0 ± 0.731.4 ± 1.37
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 1.000
SecondaryPercentage of Pain Free Episodes

A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

Time frame:
10 minutes
Reported as:
Mean · percentage of episodes
Percentage of Pain Free Episodes
percentage of episodesOnsolisPlacebo
Percentage of Pain Free Episodes1.0 ± 0.721.4 ± 1.35
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 1.000
SecondaryPercentage of Pain Free Episodes

A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

Time frame:
15 minutes
Reported as:
Mean · percentage of episodes
Percentage of Pain Free Episodes
percentage of episodesOnsolisPlacebo
Percentage of Pain Free Episodes2.3 ± 1.022.0 ± 1.48
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.563
SecondaryPercentage of Pain Free Episodes

A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

Time frame:
30 minutes
Reported as:
Mean · percentage of episodes
Percentage of Pain Free Episodes
percentage of episodesOnsolisPlacebo
Percentage of Pain Free Episodes5.3 ± 1.574.4 ± 1.88
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.498
SecondaryPercentage of Pain Free Episodes

A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

Time frame:
45 minutes
Reported as:
Mean · percentage of episodes
Percentage of Pain Free Episodes
percentage of episodesOnsolisPlacebo
Percentage of Pain Free Episodes10.5 ± 2.346.4 ± 2.27
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.077
SecondaryPercentage of Pain Free Episodes

A pain free episode is one with 0 pain intensity at the specified time point. Percentage of episodes that are pain-free per subject is analyzed.

Time frame:
60 minutes
Reported as:
Mean · percentage of episodes
Percentage of Pain Free Episodes
percentage of episodesOnsolisPlacebo
Percentage of Pain Free Episodes14.2 ± 2.629.6 ± 2.90
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.031
SecondaryEpisodes With at Least 50% Decreases in Pain

Number of episodes where the total pain score has at least a 50% reduction from baseline.

Time frame:
15 minutes
Reported as:
Mean · episodes
Episodes With at Least 50% Decreases in Pain
episodesOnsolisPlacebo
Episodes With at Least 50% Decreases in Pain14.9 ± 2.8114.7 ± 3.35
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.963
SecondaryEpisodes With at Least 50% Decreases in Pain

Number of episodes where the total pain score has at least a 50% reduction from baseline.

Time frame:
30 minutes
Reported as:
Mean · episodes
Episodes With at Least 50% Decreases in Pain
episodesOnsolisPlacebo
Episodes With at Least 50% Decreases in Pain32.8 ± 3.7824.1 ± 3.87
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.002
SecondaryEpisodes With at Least 50% Decreases in Pain

Number of episodes where the total pain score has at least a 50% reduction from baseline.

Time frame:
45 minutes
Reported as:
Mean · episodes
Episodes With at Least 50% Decreases in Pain
episodesOnsolisPlacebo
Episodes With at Least 50% Decreases in Pain41.1 ± 4.1130.5 ± 4.10
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.008
SecondaryEpisodes With at Least 50% Decreases in Pain

Number of episodes where the total pain score has at least a 50% reduction from baseline.

Time frame:
60 minutes
Reported as:
Mean · episodes
Episodes With at Least 50% Decreases in Pain
episodesOnsolisPlacebo
Episodes With at Least 50% Decreases in Pain46.1 ± 4.1734.0 ± 4.30
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.005
SecondaryEpisodes With at Least 33% Decreases in Pain

Number of episodes where the total pain score has at least a 33% reduction from baseline.

Time frame:
15 minutes
Reported as:
Mean · episodes
Episodes With at Least 33% Decreases in Pain
episodesOnsolisPlacebo
Episodes With at Least 33% Decreases in Pain26.4 ± 3.5521.3 ± 3.66
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.100
SecondaryEpisodes With at Least 33% Decreases in Pain

Number of episodes where the total pain score has at least a 33% reduction from baseline.

Time frame:
30 minutes
Reported as:
Mean · episodes
Episodes With at Least 33% Decreases in Pain
episodesOnsolisPlacebo
Episodes With at Least 33% Decreases in Pain47.3 ± 4.0538.2 ± 4.45
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.009
SecondaryEpisodes With at Least 33% Decreases in Pain

Number of episodes where the total pain score has at least a 33% reduction from baseline.

Time frame:
45 minutes
Reported as:
Mean · episodes
Episodes With at Least 33% Decreases in Pain
episodesOnsolisPlacebo
Episodes With at Least 33% Decreases in Pain57.5 ± 3.9346.5 ± 4.50
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.004
SecondaryEpisodes With at Least 33% Decreases in Pain

Number of episodes where the total pain score has at least a 50% reduction from baseline.

Time frame:
60 minutes
Reported as:
Mean · episodes
Episodes With at Least 33% Decreases in Pain
episodesOnsolisPlacebo
Episodes With at Least 33% Decreases in Pain64.3 ± 3.7248.2 ± 4.51
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryEpisodes With Complete Pain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

Time frame:
5 minutes
Reported as:
Mean · percentage of episodes
Episodes With Complete Pain Relief
percentage of episodesOnsolisPlacebo
Episodes With Complete Pain Relief0.7 ± 0.660.7 ± 0.68
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 1.000
SecondaryEpisodes With Complete Pain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

Time frame:
10 minutes
Reported as:
Mean · percentage of episodes
Episodes With Complete Pain Relief
percentage of episodesOnsolisPlacebo
Episodes With Complete Pain Relief1.0 ± 0.720.7 ± 0.68
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 1.000
SecondaryEpisodes With Complete Pain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief).Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

Time frame:
15 minutes
Reported as:
Mean · percentage of episodes
Episodes With Complete Pain Relief
percentage of episodesOnsolisPlacebo
Episodes With Complete Pain Relief1.7 ± 0.831.3 ± 0.94
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.750
SecondaryEpisodes With Complete Pain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

Time frame:
30 minutes
Reported as:
Mean · percentage of episodes
Episodes With Complete Pain Relief
percentage of episodesOnsolisPlacebo
Episodes With Complete Pain Relief5.4 ± 1.632.6 ± 1.33
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.032
SecondaryEpisodes With Complete Pain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

Time frame:
45 minutes
Reported as:
Mean · percentage of episodes
Episodes With Complete Pain Relief
percentage of episodesOnsolisPlacebo
Episodes With Complete Pain Relief9.4 ± 2.186.4 ± 2.27
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.131
SecondaryEpisodes With Complete Pain Relief

Pain relief (PR) is measured using a 5-point categorical scale (0=no relief to 4=complete relief). Percentage of episodes with complete relief per subject is analyzed where a complete pain relief episode is defined as pain relief of value 4 at the specified time point.

Time frame:
60 minutes
Reported as:
Mean · percentage of episodes
Episodes With Complete Pain Relief
percentage of episodesOnsolisPlacebo
Episodes With Complete Pain Relief12.8 ± 2.497.2 ± 2.40
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.007
SecondaryRescue Medication Usage

Rescue medication is medication taken if adequate pain relief is not realized within 30 minutes following application of the study drug. Percentage of episodes when rescue medication was used per subject is analyzed.

Time frame:
28 Days
Reported as:
Mean · percentage of episodes
Rescue Medication Usage
percentage of episodesOnsolisPlacebo
Rescue Medication Usage30.0 ± 3.5344.6 ± 4.38
Statistical analysis
  • Onsolis vs Placebo · Wilcoxon (Mann-Whitney) · p = 0.002
Other pre-specifiedSPID in Neuropathic Pain Subpopulation

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.

Time frame:
15 minutes
Reported as:
Least squares mean · Scores on a scale
SPID in Neuropathic Pain Subpopulation
Scores on a scaleOnsolisPlacebo
SPID in Neuropathic Pain Subpopulation13.8 ± 2.937.8 ± 3.20
Statistical analysis
  • Onsolis vs Placebo · Mixed Models Analysis · p = 0.023 · Mean difference (final values): 5.96 · 95% CI 0.92 to 11.01
Other pre-specifiedSPID in Neuropathic Pain Subpopulation

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.

Time frame:
30 minutes
Reported as:
Least squares mean · Scores on a scale
SPID in Neuropathic Pain Subpopulation
Scores on a scaleOnsolisPlacebo
SPID in Neuropathic Pain Subpopulation51.6 ± 8.0531.8 ± 8.86
Statistical analysis
  • Onsolis vs Placebo · Mixed Models Analysis · p = 0.009 · Mean difference (final values): 19.84 · 95% CI 5.63 to 34.04
Other pre-specifiedSPID in Neuropathic Pain Subpopulation

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.

Time frame:
45 minutes
Reported as:
Least squares mean · Scores on a scale
SPID in Neuropathic Pain Subpopulation
Scores on a scaleOnsolisPlacebo
SPID in Neuropathic Pain Subpopulation93.0 ± 14.0959.7 ± 15.63
Statistical analysis
  • Onsolis vs Placebo · Mixed Models Analysis · p = 0.012 · Mean difference (final values): 33.26 · 95% CI 8.32 to 58.20
Other pre-specifiedSPID in Neuropathic Pain Subpopulation

Pain intensity (using an 11-point \[0 = no pain to 10 = worst pain\] numeric scale) was recorded at 0, 5, 10, 15, 30, 45, and 60 minutes after dosing. Pain intensity difference (PID) was defined as the baseline pain score minus the pain score of each time point. The primary endpoint was the Summary of Pain Intensity Differences at 30 minutes after dosing (SPID 30) in ITT population for Onsolis versus placebo during double-blind period of study. SPID was calculated as a weighted sum of the PID of all time points at or before time point of interest.Range of possible SPID values is -10X time point (minutes) to 10X time point (minutes). Higher value indicates a better outcome. SPID was calculated as a weighted sum of the pain intensity difference of all time points at or before the time point of interest for the Neuropathic pain subpopulation for relevant time points (15, 30, 45, 60 minutes). Neuropathic pain subpopulation is a subset of ITT population who have neuropathic pain at baseline.

Time frame:
60 minutes
Reported as:
Least squares mean · Scores on a scale
SPID in Neuropathic Pain Subpopulation
Scores on a scaleOnsolisPlacebo
SPID in Neuropathic Pain Subpopulation137.8 ± 20.1990.9 ± 22.53
Statistical analysis
  • Onsolis vs Placebo · Mixed Models Analysis · p = 0.015 · Mean difference (final values): 46.88 · 95% CI 10.69 to 83.08

Adverse events

Collected over A prior-treatment adverse event (AE) was defined as an AE that began before the first dose of the study drug. A treatment-emergent AE was defined as an AE that began on or after the initial dose of study medication up until the Follow-up Visit on Day 29.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Onsolis—23/151 (15.2%)44/151 (29.1%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventOnsolis
PneumoniaInfections and infestations6/151
DehydrationMetabolism and nutrition disorders2/151
SplenomegalyBlood and lymphatic system disorders1/151
Gastrointestinal hemorrhageGastrointestinal disorders1/151
HematemesisGastrointestinal disorders1/151
Intestinal obstructionGastrointestinal disorders1/151
Esophageal hemorrhageGastrointestinal disorders1/151
PyrexiaGeneral disorders1/151
Bile duct obstructionHepatobiliary disorders1/151
Hepatic failureHepatobiliary disorders1/151
Most frequent other events
Most frequent other events
EventOnsolis
NauseaGastrointestinal disorders21/151
VomitingGastrointestinal disorders19/151
SomnolenceNervous system disorders10/151
DehydrationMetabolism and nutrition disorders7/151
DizzinessNervous system disorders7/151

Baseline characteristics

Safety Population

Age, Categorical
Age, Categorical(Participants)Onsolis
<=18 years0
Between 18 and 65 years104
>=65 years47
Age, Continuous
Age, Continuous(years)Onsolis
Mean57.1 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Onsolis
Female85
Male66
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Onsolis
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American12
White131
More than one race0
Unknown or Not Reported7
Region of Enrollment
Region of Enrollment(participants)Onsolis
United States151
Female reproductive status
Female reproductive status(Participants)Onsolis
Post-menopausal43
Sterile38
Potentially able to bear children3
Male67
Height (inches)
Height (inches)(Inches)Onsolis
Mean66.4 ± 3.86
Weight (pounds)
Weight (pounds)(pounds)Onsolis
Mean160.89 ± 42.011
08

Study locations

1 site
  • PPD Development
    Wilmington, North Carolina 28412, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Apr 2007 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 12 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2006
First posted
Feb 17, 2006
Start
Feb 2006
Primary completionActual
Apr 2007
CompletionActual
Apr 2007
Results first posted
Oct 21, 2019
Last update
Nov 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00293033
Lead sponsor
BioDelivery Sciences International
Responsible party
Sponsor
First posted
Feb 17, 2006
Start date
Feb 2006
Primary completion
Apr 2007
Completion
Apr 2007
Results posted
Oct 21, 2019
Last update
Nov 18, 2019

Study contacts

Andrew Finn, PharmD
study chair · BioDelivery Sciences International

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion